AI Article Synopsis

  • Autoimmune polyglandular syndrome 1 (APS1) is a genetic disorder characterized by multiple autoimmune issues, including candidiasis, hypoparathyroidism, and adrenal insufficiency, caused by mutations in the autoimmune regulator gene.
  • A case study of a 39-year-old woman with APS1 highlighted her severe health challenges, including childhood fungal infections that led to a bone marrow transplant and adult-onset partial lipodystrophy marked by significant fat loss.
  • Research showed pathogenic variants in her genetic profile and the presence of specific autoantibodies, suggesting potential links to fat tissue issues, though the exact cause of her lipodystrophy remains unclear.

Article Abstract

Autoimmune polyglandular syndrome 1 (APS1) is an autosomal recessive disorder due to biallelic pathogenic variants in the autoimmune regulator () gene that manifests with chronic mucocutaneous candidiasis, primary hypoparathyroidism, and adrenal insufficiency. We report a 39-year-old woman with APS1 who developed partial lipodystrophy during adulthood. She presented with diaper rashes, oral thrush, and tetany during infancy due to candidiasis and hypoparathyroidism. During childhood, she developed hypothyroidism, primary adrenal insufficiency, and ovarian insufficiency. At age 14, she received a sibling-matched allogenic bone marrow transplant due to multiple antibiotic-refractory fungal infections. At age 35, her serum triglycerides were 914 mg/dL (10.32 mmol/L) and she had loss of subcutaneous fat from the upper and lower extremities and hips. A whole-body dual-energy x-ray absorptiometry revealed lower-extremity fat at less than the first percentile. Whole-exome sequencing on DNA extracted from saliva revealed pathogenic variants, p.Leu28Pro and p.Arg257* in but none in the known lipodystrophy genes. Phage-immunoprecipitation-sequencing revealed the presence of autoantibodies to MAGEB1, MAGEB4, and RFX6, which have been previously reported in APS1. Our case suggests that patients with APS1 may develop partial lipodystrophy due to autoantibodies against novel adipocyte-expressed proteins. A causal relationship of high levels of autoantibodies in our patient to adipose tissue-expressed ODC1, NUCKS1, or FNBP1L and lipodystrophy remains uncertain.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421462PMC
http://dx.doi.org/10.1210/jcemcr/luae166DOI Listing

Publication Analysis

Top Keywords

partial lipodystrophy
12
autoimmune polyglandular
8
polyglandular syndrome
8
pathogenic variants
8
adrenal insufficiency
8
lipodystrophy extremities
4
extremities young
4
young woman
4
woman autoimmune
4
syndrome autoimmune
4

Similar Publications

The Causal Role of Ectopic Fat Deposition in the Pathogenesis of Metabolic Syndrome.

Int J Mol Sci

December 2024

Department of Internal Medicine, Erasmus Medical Center (Erasmus MC), Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.

Consuming a "modern" Western diet and overnutrition may increase insulin secretion. Additionally, nutrition-mediated hyperinsulinemia is a major driver of ectopic fat deposition. The global prevalence of metabolic syndrome is high and growing.

View Article and Find Full Text PDF

Loss of Mfn1 but not Mfn2 enhances adipogenesis.

PLoS One

December 2024

Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom.

Objective: A biallelic missense mutation in mitofusin 2 (MFN2) causes multiple symmetric lipomatosis and partial lipodystrophy, implicating disruption of mitochondrial fusion or interaction with other organelles in adipocyte differentiation, growth and/or survival. In this study, we aimed to document the impact of loss of mitofusin 1 (Mfn1) or 2 (Mfn2) on adipogenesis in cultured cells.

Methods: We characterised adipocyte differentiation of wildtype (WT), Mfn1-/- and Mfn2-/- mouse embryonic fibroblasts (MEFs) and 3T3-L1 preadipocytes in which Mfn1 or 2 levels were reduced using siRNA.

View Article and Find Full Text PDF

Acquired generalized lipodystrophy (AGL) is a rare complication of immune checkpoint inhibitors (ICIs) and is associated with immune-mediated loss of adipose tissue, peripheral resistance to insulin, and serious metabolic complications. Here we report a new case of ICI-induced AGL and provide an updated literature review of published cases. We report a 39-year-old female patient treated with adjuvant pembrolizumab for stage IIIC nevoid melanoma with ICI-induced AGL.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!